• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mei Pharma Inc (NQ: MEIP )

    2.820 +0.020 (+0.71%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Jul 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,818
    Open 2.780
    Bid (Size) 2.750 (2)
    Ask (Size) 2.990 (2)
    Prev. Close 2.800
    Today's Range 2.780 - 2.820
    52wk Range 2.729 - 7.873
    Shares Outstanding 6,662,857
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    7 Undervalued Biotech Stocks to Buy for Big-Time Returns
    The broader healthcare sector enjoys a powerfully relevant narrative. Undervalued biotech stocks makes the case even more attractive. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga

    Performance

    YTD
    -53.08%
    -53.08%
    1 Month
    -1.05%
    -1.05%
    3 Month
    -26.37%
    -26.37%
    6 Month
    -50.96%
    -50.96%
    1 Year
    -57.21%
    -57.21%

    More News

    Read More
    Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024
    Via InvestorPlace
    MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
    From MEI Pharma, Inc.
    Via Business Wire
    5 Value Stocks In The Healthcare Sector
    Via Benzinga
    Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024
    From MEI Pharma, Inc.
    Via Business Wire
    A Look Into Healthcare Sector Value Stocks
    Via Benzinga
    Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP)
    From Glancy Prongay & Murray LLP
    Via Business Wire
    MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023
    From MEI Pharma, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma to Present at the Stifel 2023 Healthcare Conference
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common Stock
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Enters into Agreement with Anson Funds and Cable Car Capital
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Recommends Stockholders Not to Consent
    From MEI Pharma
    Via Business Wire
    MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
    From MEI Pharma, Inc.
    Via Business Wire
    MEI Pharma Issues Statement Regarding Anson and Cable Car’s Opportunistic Actions
    From MEI Pharma, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.